Federal Appellate Court Applies Preemption In Reversing Verdict Against Pharmaceutical Company
The United States Court of Appeals for the Fourth Circuit (“Federal Appellate Court”) held in its published opinion dated January 6, 2020: “Boehringer [Boehringer Ingelheim Pharmaceuticals, Inc.] did not have “newly acquired information” regarding an optimal Pradaxa blood conce[...]